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COMMENTARY
Endpoints in Phase II Trials for Advanced Non-small Cell
Lung Cancer
Sumithra J. Mandrekar, PhD,* Yingwei Qi, MD, MS,* Shauna L. Hillman, MS,*
Katie L. Allen Ziegler, BS,* Nicholas F. Reuter, MD,† Kendrith M. Rowland, Jr., MD,‡
Steven A. Kuross, MD,§ Randolph S. Marks, MD,* Steven E. Schild, MD,
and Alex A. Adjei, MD, PhD¶
Introduction: We investigated the relationships between progres-
sion-free survival (PFS), response, confirmed response, and failure-
free survival (FFS) with overall survival (OS) to assess their suit-
ability as primary endpoints in phase II trials for advanced non-small
cell lung cancer.
Methods: Individual data of 284 patients from four phase II trials
were pooled. Progression status and response were modeled as time
dependent variables in a multivariable (adjusted for baseline age,
gender, stage, and performance status) Cox proportional hazards
model for OS, stratified by trial. Subsequently, Cox proportional
hazards models were used to assess the impact of PFS, response,
confirmed response, and FFS on subsequent survival, using land-
mark analysis at 8, 12, 16, 20, and 24 weeks. Model discrimination
was evaluated using the concordance index (c-index).
Results: The overall median OS, PFS, and FFS were 9.6, 3.7, and
2.8 months, and the response and confirmed response rates were 21
and 15%, respectively. Both progression status and response as time
dependent covariates were significantly associated with OS (p 
0.0001; p 0.009). PFS and FFS at 12 weeks significantly predicted
for subsequent survival with the strongest c-index and hazard ratio
combination in landmark analyses (hazard ratio, c-index: PFS: 0.39,
0.67; FFS: 0.37, 0.67). The c-indices for response and confirmed
response were low (0.59–0.60), indicating their inability to suffi-
ciently discriminate subsequent patient survival outcomes.
Conclusions: FFS or PFS at 12 weeks is a stronger predictor of
subsequent patient survival compared with tumor response and
should be routinely used as endpoints in phase II trials for advanced
non-small cell lung cancer.
Key Words: Advanced NSCLC, Endpoints, Failure-free survival,
Progression-free survival, Tumor response.
(J Thorac Oncol. 2010;5: 3–9)
Approximately 55% of patients with non-small cell lungcancer (NSCLC) have advanced disease (stage IIIB with a
positive pleural effusion or stage IV) at diagnosis and are
generally considered incurable.1 Although progress has been
made, the survival of patients with advanced NSCLC remains
poor, with a median overall survival (OS) of 6 to 12 months, and
1-year survival rates between 20 and 50%.2,3 More recently, a
phase II trial of chemotherapy with targeted agents (Bevaci-
zumab and Cetuximab) demonstrated a median OS of 14 months
and a median progression-free survival (PFS) of 7 months.4 A
phase III trial with this combination is currently in development.
Given the dismal prognosis of this disease, it is critical to rapidly
screen new treatments and move forward promising therapies
for definitive results. Although OS remains the gold standard
end point that unequivocally assesses the benefit of a new
treatment relative to the current standard of care, it requires more
follow-up in some cases making it a “long” end point to assess,
especially in a phase II setting where time is of the essence. The
ability to rapidly identify patients not benefiting from the current
therapy and give them alternate “effective” therapies is in the
best interest of the patient. Another potential challenge to OS as
an end point is the inability to effectively assess crossover effects
and subsequent therapies on disease progression. Thus, it is
critical to identify valid alternative endpoints to replace OS as
the primary end point in phase II clinical trials. We undertook
this investigation using data from previously conducted phase II
trials in advanced NSCLC.
Controversies surrounding tumor burden assessment have
been reported in the literature, specifically, the high inter- and
intraobserver variability in NSCLC lesion measurement,5 and a
lack of correlation between response and OS.6 Nevertheless,
tumor response is a historically accepted end point to assess
clinical benefit in phase II trials. The RECIST was implemented
in an effort to standardize assessment of tumor response and has
been widely used in cancer clinical trials since 2000.7 Per
RECIST, measurable target lesions (up to a maximum of 10)
representative of all the involved organs are identified, recorded,
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and measured at baseline using unidimensional tumor measure-
ments. The overall objective status is then determined based on
the assessment of the target lesions, nontarget lesions, and new
lesions. Best response is defined as the best objective status (i.e.,
complete or partial response, stable disease [SD], or progression)
on treatment. Confirmed response is defined as two consecutive
assessments of complete or partial response assessed at least 4
weeks apart. Thus, by definition, confirmed response, in contrast
to best response, requires that the response status of the
patient is sustained for at least a period of 4 weeks, thus
avoiding to some extent overestimation of the observed
response rate because of the repeat assessment. This is par-
ticularly important in nonrandomized trials where tumor
response is the primary end point.
With the advent of targeted therapies that prolong
disease stabilization, patients typically experience SD rather
than tumor shrinkage. It has been shown that patients with SD
also achieve clinical benefit,8 and hence, it is not appropriate
to ignore SD when assessing treatment efficacy. Therefore,
PFS rate has become an accepted alternate end point in
assessing treatment efficacy as it includes a patient who
achieves SD for an extended period of time as a success, in
addition to those who achieve complete or partial response.
The typical time point(s) at which the PFS status is evaluated
in a phase II trial for advanced NSCLC is between 8 and 24
weeks (typically around 16–24 weeks) given the median PFS
for this disease population. PFS is defined as the time from
registration or randomization to the earlier of disease pro-
gression or death from any cause. By virtue of this definition,
PFS, unlike OS, is a measure of both the efficacy and tumor
growth associated with the initial therapy, unaffected by any
subsequent treatment on disease progression. In a disease
with poor prognosis such as advanced NSCLC, it can be
argued that the true end point of OS is probably mostly
determined by the progression status of the disease. However,
issues pertaining to ascertainment bias in an open label trial,
imbalance in assessment dates across the different arms,
missing assessments, treatment holidays, and/or occurrence
of progression in the middle of a long disease evaluation
interval can affect the accuracy and validity of PFS as an end
point and need to be carefully considered. Another end point
similar in principle to PFS is failure-free survival (FFS),
where failure is defined as treatment termination from any
cause (i.e., death, progression, adverse events, patient refusal,
or any other unspecified reasons). FFS, by definition, there-
fore requires patients to be on treatment to be considered a
success. Thus, the differences between FFS and PFS as
defined here are (1) PFS, unlike FFS, defines success as
progression-free and alive regardless of the patient being on
or off study treatment and (2) FFS, unlike PFS, includes any
reason to terminate treatment as a failure.
In this pooled analysis, we formally investigated the rela-
tionships between PFS, response, confirmed response, and FFS
with OS using individual patient data from four phase II trials
conducted by the North Central Cancer Treatment Group. Spe-
cifically, we evaluated the impact of these endpoints at different
time points during treatment on patient survival.
MATERIALS AND METHODS
Identification of Trials
Individual patient data were pooled from four consecutive
North Central Cancer Treatment Group phase II trials (N0026,
N0323, N0326, and N0426) in advanced NSCLC (Stage IIIB
with pleural effusion and Stage IV, based on the 6th edition of
lung cancer staging) conducted between 2001 and 2007.9–12 The
trial regimens included Docetaxel, Gemcitabine, Pemetrexed,
Temsorilimus, Sorafenib, and Bevacizumab. All trials except
N0026 were negative for the protocol defined primary end point.
All trials used the RECIST7 criteria for tumor response assess-
ment, and the evaluations were performed by the local treating
physician.
Patients enrolled on trials N0026 and N0426 were on an
every 3-week treatment schedule, with tumor assessments
done at least every 6 weeks. Patients enrolled on trials N0323
and N0326 were on an every 4-week treatment schedule with
tumor assessments done at least every 8 weeks. See Table 1
for information on the individual trial characteristics, and
Table 2 for the expected number of assessments and the mean
and range of the actual number of assessments by trial at
different time points. Because of the treatment and tumor
assessment schedules, objective status at 8 weeks was based
on only one postbaseline assessment on all trials, and objec-
tive status at 12 weeks was based only on one postbaseline
assessment in two of the four trials. However, all trials required
a tumor assessment on a patient at any time during a treatment
cycle when disease progression was clinically suspected. The
reporting of disease progression was therefore more real time
than just at the predefined time points. The 8- and 12-week time
points could be considered too early for a meaningful analysis of
response, but are included here for the sake of completeness
when comparing with the PFS and FFS endpoints.
TABLE 1. Individual Trial Characteristics
Trial Open Date Close Date
No. of Evaluable
Patients Regimen
Treatment
Schedule
ECOG
PS Previous Brain Metastases
N0026 August 10, 2001 May 27, 2003 157 Pemetrexed, gemcitabine q 21 d 0–1 Not allowed
N0323 February 27, 2004 November 03, 2006 54 Temsirolimus q 28 d 0–2 Not allowed
N0326 December 31, 2004 August 04, 2006 25 Sorafenib q 28 d 0–2 Not allowed
N0426 May 19, 2006 February 23, 2007 48 Pemetrexed, bevacizumab q 21 d 0–2 Symptomatic, untreated, or
uncontrolled metastases not
allowed
PS, performance status; ECOG, Eastern Cooperative Oncology Group.
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Statistical Analysis
Objective status was assessed using the RECIST7 cri-
teria in all trials. A success for response included either
partial or complete response as the best objective status at any
time while on treatment, and a success for confirmed re-
sponse included two consecutive assessments of complete or
partial response at least 4 weeks apart. OS is defined as the
time from registration/randomization to death from any
cause. PFS is defined as the time from registration/random-
ization to the date of first documented disease progression or
death, regardless of patient being on or off study treatment.
FFS is defined as the time from registration/randomization to
treatment termination due to any cause (ie, death, disease
progression, patient refusal, adverse events, etc.).
As the first step, both progression status and response
were modeled as time dependent variables in multivariable
(adjusted for stage, age, gender, and performance status [PS])
Cox proportional hazards models for OS, stratified for the
patient’s trial. This was done to assess whether patients who
remained progression-free or had achieved a response at any
time during treatment survived significantly longer than those
who had progressed or not responded to treatment. Subse-
quently, univariable and multivariable Cox proportional hazards
models, stratified for the patient’s trial, were used to assess the
prognostic impact of PFS, response, confirmed response, and
FFS on subsequent survival using a landmark analysis (with 8,
12, 16, 20, and 24 weeks postregistration as baseline). The
hazard ratios (HR) and 95% confidence intervals (CI) are
reported.
Model discrimination (i.e., ability to discriminate patients
with different survival times) was evaluated using the concor-
dance index (c-index) for the landmark analyses.13 The c-index
computes the probability that, for a pair of randomly chosen
comparable patients, the patient with the higher risk prediction
will experience an event before the lower risk patient. A com-
pletely random prediction would have a c-index of 0.5, and a
perfect rule will have a concordance of 1.0. All analyses were
performed using SAS v9.13 and Splus 8.01.
RESULTS
Patient Characteristics and Outcomes
Data was frozen on March 25, 2009. One patient was
excluded because of withdrawal from study before receiving
study treatment, thus, a total of 284 patients were included in
this analysis. Table 3 summarizes the baseline characteristics
and outcomes of the four trials included in this pooled
analysis. The median age was 65 years (range, 39–85), with
61% of patients being men. The majority (87%) of patients
had stage IV disease and good PS (39% PS  0, 57% PS 
1). Information on histology was collected only on one trial
(N0026): 21% of patients had squamous and 79% of patients
had nonsquamous histology as determined by a central pa-
thology review.
TABLE 2. Expected and Actual Number of Tumor
Assessments by Trial
No. of Expected Assessments (No. of Actual Assessments: Mean, Range)
Time Point N0026a N0323b N0326b N0426a
8 wk 1 (0.9, 0–2) 1 (1.2, 0–2) 1 (1.0, 0–2) 1 (0.9, 0–1)
12 wk 2 (1.5, 0–4) 1 (1.4, 0–3) 1 (1.2, 0–2) 2 (1.4, 0–2)
16 wk 2 (1.6, 0–5) 2 (1.7, 0–4) 2 (1.6, 0–3) 2 (1.5, 0–3)
20 wk 3 (1.9, 0–6) 2 (1.8, 0–5) 2 (1.7, 0–3) 3 (1.9, 0–4)
24 wk 4 (2.2, 0–8) 3 (2.0, 0–6) 3 (1.8, 0–3) 4 (2.2, 0–4)
a Tumor assessment every 2 cycles (i.e., 6 wk).
b Tumor assessment every 2 cycles (i.e., 8 wk).
TABLE 3. Baseline Patient Characteristics and Outcomes by Trial
N0026 (n  157)
N (%)
N0323 (n  54)
N (%)
N0326 (n  25)
N (%)
N0426 (n  48)
N (%)
Total (n  284)
N (%)
Patient characteristics
Age in yrs, median (range) 65 (39–85) 65 (44–85) 67 (45–85) 65 (43–78) 65 (39–85)
Gender
Male 95 (60.5) 33 (61.1) 10 (40.0) 34 (70.8) 172 (60.6)
Female 62 (39.5) 21 (38.9) 15 (60.0) 14 (29.2) 112 (39.4)
Performance status
0 56 (35.7) 25 (46.3) 12 (48.0) 17 (35.4) 110 (38.7)
1 101 (64.3) 24 (44.4) 10 (40.0) 26 (54.2) 161 (56.7)
2 0 (0.0) 5 (9.3) 3 (12.0) 5 (10.4) 13 (4.6)
Stage
IIIB 20 (12.7) 10 (18.5) 4 (16.0) 3 (6.2) 37 (13.0)
IV 137 (87.3) 44 (81.5) 21 (84.0) 45 (93.8) 247 (87.0)
Summary of outcomes
Median overall survival (mos) 10.8 6.6 8.8 8.6 9.6
Median progression-free survival (mos) 4.1 2.3 2.8 4.0 3.7
Median failure-free survival (mos) 2.9 2.0 2.2 3.4 2.8
Response 43 (27) 7 (13) 4 (16) 7 (14) 61 (21)
Confirmed response 30 (19) 4 (7) 3 (12) 5 (10) 42 (15)
Journal of Thoracic Oncology • Volume 5, Number 1, January 2010 Endpoints in Phase II Trials
Copyright © 2009 by the International Association for the Study of Lung Cancer 5
The median follow-up time for the 24 alive patients was
2.5 years (range, 0.3–6.0). Ninety two percent of patients had
died (7% died on treatment) and 87% of patients had disease
progression at the time of this analysis (13% died without
disease progression). The primary causes of death in the
patients who died without disease progression included clin-
ical deterioration without documented evidence of disease
progression (59%) and adverse events unrelated to the disease
(41%). The overall median OS, PFS, and FFS was 9.6 months
(95% CI, 8.7–11.1), 3.7 months (95% CI, 2.9–4.3), and 2.8
months (95% CI, 2.1–3.3), respectively. See Figures 1A–C
for Kaplan-Meier curves for OS, PFS, and FFS. The overall
response and CR rates were 21% (95% CI, 16.9–26.7) and
15% (95% CI, 10.9–19.5), respectively.
Approximately, 26.4, 34.9, 42.6, 52.5, and 56.3% of
patients had disease progression by 8, 12, 16, 20, and 24 weeks,
respectively, poststudy entry. Ten patients had identical progres-
sion and survival times, i.e., died of disease progression. For the
246 patients who had progressed at the time of this analysis, the
median time from progression to death was 5.7 months (95%CI,
4.6–7.1), with 52.9% of patients dying within 6 months after
disease progression. The median time from treatment termina-
tion to death was 5.7 months (95%CI, 4.6–7.5). Approximately,
10.7% of patients who ended study treatment by 12 weeks for
reasons other than disease progression (refusal, adverse event,
alternate treatment, and other medical problems) remained pro-
gression free at 12 weeks.
Time Dependent Models
The results from the time dependent models for progres-
sion status and response are summarized in Table 4. At any
given time, the hazard for a patient who had disease progression
by that time was 7.0 times the hazard for a patient who had not
progressed, under the assumption that the two patients were
otherwise similar in age, stage, PS, and gender at baseline
(Model 1, Table 4). Although response as a time dependent
covariate was also significantly associated with OS, the effect
was more modest in terms of HR, p value, and 2 statistic
FIGURE 1. Kaplan-Meier curves for overall sur-
vival (A), progression-free survival (B), and failure-
free survival (C).
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(Model 2, Table 4). In addition, PS was a significant predictor
with PS 2 and PS 1 patients having a worse outcome compared
with PS 0 patients in both models; and age and gender were
significant predictors in model 2 (for response) with older
patients and males having a worse prognosis.
Landmark Analysis
Two hundred fifty nine, 242, 227, 215, and 197 patients
who were alive at 8, 12, 16, 20, and 24 weeks poststudy entry
were included in the respective landmark analysis.
Univariable Model Results
Although patients who had achieved a response or
confirmed response at some of the landmark time points had
significantly longer subsequent survival, the c-indices of
these models were low (0.53–0.54), indicating an inability of
these metrics to discriminate patients with different survival
times. In contrast, patients who were alive and progression-
free (in the case of PFS), or who continued to stay on
treatment (in the case of FFS) at the different landmark time
points did significantly better in terms of subsequent survival
compared with those who had progressed, died, or ended
treatment for any reason. The c-indices ranged from 0.58 to
0.63, and the HRs ranged from 0.37 to 0.46. PFS status at 12,
16, 20, and 24 weeks were each predictive of subsequent
survival with c-index of 0.61, 0.61, 0.63, and 0.63 respec-
tively. FFS status at 12 weeks had the highest c-index of 0.62.
Multivariable Model Results
After adjusting for baseline age, gender, stage, and PS,
models including confirmed response by 16 and 20 weeks as
predictors had a c-index of 0.60 and p  0.05; however, only
12 and 16% of patients had achieved a confirmed response by
16 and 20 weeks (Model 2, Table 5). The results for PFS and
FFS were consistent with the univariable analysis (Models 3
and 4, Table 5). The PFS as well as the FFS status at all of the
landmark time points were significantly associated with OS.
The c-indices were similar for PFS status at 12, 16, 20,
and 24 weeks (0.66–0.68), and for FFS status at all the
landmark time points (0.64–0.67). The HRs for PFS and FFS
ranged from 0.39–0.49 and 0.37–0.46, respectively. Looking
at a combination of HR and c-index, PFS status at 12 weeks
and FFS status at 12 weeks were the most predictive of
subsequent survival. Patients who remained alive and pro-
gression-free at 12 weeks (PFS), or who continued to be on
treatment at 12 weeks (FFS) had a significantly better prog-
nosis in terms of subsequent survival. See Table 5 for the
detailed multivariable landmark analysis results.
In summary, PFS or FFS status as early as 12 weeks is
a strong predictor of subsequent survival. Figures 2A, B show
the Kaplan-Meier curves for OS split by the landmark anal-
ysis subgroups: PFS status at 12 weeks and FFS status at 12
weeks. The median OS for patients who were progression-
TABLE 4. Results from the Multivariable Cox Proportional
Hazards Models with 1) Progression and 2) Best Response,
as Time Dependent Covariates
Factor Chi-Square
Hazard Ratio
(95% CI) p
Model 1
Progression vs. no
progression
82.72 7.03 (4.62–10.70) 0.0001
Age (1 unit increase) 2.29 1.01 (1.00–1.02) 0.13
Stage IV vs. stage IIIB
w/pleural effusion
0.40 1.13 (0.78–1.65) 0.53
PS 1 vs. PS 0 8.19 1.50 (1.14–1.97) 0.004
PS 2 vs. PS 0 16.98 4.06 (2.08–7.90) 0.0001
Females vs. males 2.38 0.82 (0.63–1.06) 0.12
Model 2
Response vs. othersa 6.74 0.66 (0.48–0.90) 0.009
Age (1 unit increase) 4.47 1.01 (1.00–1.03) 0.03
Stage IV vs. stage IIIB
w/pleural effusion
2.18 1.33 (0.91–1.93) 0.14
PS 1 vs. PS 0 9.07 1.53 (1.16–2.01) 0.003
PS 2 vs. PS 0 17.06 3.96 (2.06–7.60) 0.0001
Females vs. males 3.50 0.78 (0.61–1.01) 0.06
a Response, complete or partial response.
TABLE 5. Landmark Analysis Results from Multivariable
(Adjusted for Age, Stage, Gender, and Performance Status)
Cox Proportional Hazards Models
Models
Percent
Successa
Hazard Ratio
(95% CI) p
Concordance
(C) Index
1. Response vs.
others
8 wk 13.5 0.62 (0.42–0.92) 0.02 0.59
12 wk 19.4 0.70 (0.49–0.99) 0.04 0.59
16 wk 20.3 0.72 (0.50–1.03) 0.07 0.59
20 wk 24.2 0.76 (0.54–1.08) 0.12 0.59
24 wk 27.4 0.75 (0.53–1.06) 0.11 0.61
2. Confirmed
response
vs. others
8 wk 0.0 n/a n/a n/a
12 wk 9.1 0.57 (0.35–0.92) 0.02 0.59
16 wk 11.5 0.59 (0.38–0.93) 0.02 0.60
20 wk 15.8 0.66 (0.44–0.99) 0.05 0.60
24 wk 18.8 0.69 (0.46–1.03) 0.07 0.61
3. Alive and
progression-
free vs.
others (PFS)
8 wk 77.6 0.45 (0.33–0.62) 0.0001 0.63
12 wk 69.4 0.39 (0.28–0.52) 0.0001 0.67
16 wk 62.6 0.49 (0.36–0.65) 0.0001 0.66
20 wk 52.6 0.41 (0.30–0.55) 0.0001 0.68
24 wk 49.2 0.41 (0.30–0.57) 0.0001 0.68
4. Alive and on
treatment vs.
others (FFS)
8 wk 69.1 0.42 (0.31–0.56) 0.0001 0.64
12 wk 59.9 0.37 (0.28–0.49) 0.0001 0.67
16 wk 53.7 0.46 (0.34–0.62) 0.0001 0.66
20 wk 41.4 0.46 (0.34–0.63) 0.0001 0.65
24 wk 35.0 0.40 (0.28–0.58) 0.0001 0.64
a Success (for each model) is defined as the percentage of patients who had: 1)
response, 2) confirmed response, 3) alive and progression-free, or 4) alive and on
treatment, at each time point.
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free at 12 weeks was significantly higher compared with
patients who had progressed by 12 weeks (median OS, 12.2
months versus 3.7 months; p  0.0001). Similarly, the
median OS for patients who remained on treatment at 12
weeks was higher compared with those who had discontinued
treatment before 12 weeks (median OS, 12.8 months versus
4.7 months; p  0.0001).
DISCUSSION
In this pooled analysis, we formally investigated the ap-
propriateness of response, confirmed response, PFS, and FFS as
alternative endpoints to OS in phase II trials for advanced
NSCLC. All trials included in this analysis used the RECIST
criteria to determine the objective status and followed either an
every 6- or an every 8-week schedule for tumor assessments.
Both progression status and response, when considered as time
dependent covariates, were significantly associated with OS.
Based on the landmark analysis, PFS or FFS status as early as 12
weeks were strongly predictive of subsequent survival, with
patients who continued to be on treatment at 12 weeks in the
case of FFS, or alive and progression-free at 12 weeks in the
case of PFS having a significantly better prognosis in terms of
OS. After adjusting for patient age, gender, stage, and PS, the
c-index was 0.67 for both PFS and FFS status at 12 weeks, thus
indicating good discriminative ability to predict subsequent
patient survival outcomes.
Not surprisingly, both PFS and FFS endpoints pro-
duced similar results as the primary reason for patients ending
treatment in a disease like advanced NSCLC is disease
progression. Note that only 10.7% of patients in this analysis
who terminated treatment by 12 weeks for reasons other than
disease progression remained progression-free at 12 weeks.
This brings up an interesting question of using either PFS or
FFS as an end point in this disease setting. Within the
framework of this analysis, this question cannot be clearly
answered as the same definitions for disease progression were
used in the FFS end point as the PFS end point.
There are some limitations to this analysis. All the trials
except N0026 included in our analysis were negative for the
primary end point per protocol, which could influence our
conclusions regarding the predictive ability of the different
metrics (PFS, FFS, response, and confirmed response) on OS.
The relatively small sample size (N  284), different tumor
response evaluation schedules (every 6 versus 8 weeks), and
the lack of a control arm (for example, platinum containing
regimen) restricted the scope of this analysis. Specifically, a
formal surrogate end point validation, which requires both a
patient-level and trial-level validation on data from multiple
controlled phase III trials was not possible. Surrogacy vali-
dation stipulates that an ideal surrogate end point must not
only highly correlate with the true end point but also fully
capture the net effect of a treatment on the true end point or
the effect of treatment on the surrogate end point must
accurately predict the effect of treatment on the true end
point.14,15 However, the reality is that the majority of phase II
trials are single arm trials, which makes surrogacy validation
FIGURE 2. Kaplan-Meier curves for overall sur-
vival in the landmark analysis subset (A) progres-
sion-free survival (PFS) status at 12 weeks and (B)
failure-free survival (FFS) status at 12 weeks.
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based on phase II data difficult, if not impossible. In such
cases, the analytical approach similar to what is done in this
pooled analysis is valid and appropriate.16
Although surrogate end point validation has been exten-
sively studied in colorectal cancer, breast cancer, and glioblas-
tomas, there has not been a consistent effort to look at alternative
endpoints to OS in advanced NSCLC in either the phase III or
the phase II setting.17–21 A large landmark survival analysis in
advanced NSCLC (N 984) concluded that disease control rate
at 8 weeks (defined as the rate of nonprogression) is a stronger
predictor of subsequent survival outcomes after platinum-based
chemotherapy than the traditional best response.16 Although our
current analysis also indicated that PFS status (or disease control
rate) at 8 weeks is a significant predictor of subsequent patient
survival, the c-index and the HR for PFS status at 12 weeks was
stronger. Another recent study explored the surrogacy of PFS for
OS in advanced NSCLC (N 2838, randomized in 7 trials) by
assessing the association between these two time-to-event end-
points and between the treatment effects on these endpoints
estimated by HR.22 This study demonstrated that PFS is a good
candidate surrogate end point for OS in advanced NSCLC trials.
Our present findings (based on data from phase II trials) are
consistent with the above results and demonstrate that PFS (and
FFS) is a significant predictor of patient survival in advanced
NSCLC.
In conclusion, this pooled analysis using individual
patient data from multiple phase II trials demonstrated that
progression status of a patient, when considered as a time
dependent covariate to account for the time to disease pro-
gression, is significantly associated with OS. PFS status or
FFS status at 12 weeks were superior endpoints to tumor
response in predicting for subsequent survival in advanced
NSCLC, with patients who continued to be on treatment at 12
weeks in the case of FFS, or alive and progression-free at 12
weeks regardless of being on or off study treatment in the
case of PFS having a significantly better prognosis in terms of
OS. Given that disease progression is the primary reason for
patients with advanced NSCLC to terminate treatment, we
recommend either end point, PFS or FFS, in place of tumor
response in phase II trials for advanced NSCLC.
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